Mana.bio raises $19.5m for AI-based lipid nanoparticle delivery platform
The platform is said to detect and optimise new, customisable LNPs to safely and effectively deliver RNA and…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
11 Oct 23
The platform is said to detect and optimise new, customisable LNPs to safely and effectively deliver RNA and…
11 Oct 23
Tevogen.ai will bring together a dedicated team of research scientists, physicians, data scientists, and AI/machine learning (ML) engineers…
10 Oct 23
The biotechnology firm intends to use the funds to develop its proprietary technology platform and expedite the development…
10 Oct 23
Strategic Financial Sponsor to Support Continued Growth and Market Expansion
06 Oct 23
Under the agreement, Biovectra will use Acuitas’ LNP technology platform on a non-exclusive basis to manufacture the mRNA-based…
05 Oct 23
The new draft guidance reveals the US regulator’s current views on developing drugs and biologics for stimulant use…
05 Oct 23
Under the collaboration, both firms will co-develop and co-commercialise Teva's anti-TL1A drug, TEV’574 asset, which is currently in…
05 Oct 23
The funding round was spearheaded by Kurma Partners' Growth Opportunities Fund, with active involvement from established investors like…
04 Oct 23
The expanded collaboration combines Intellia’s genome editing platform with Regeneron’s proprietary antibody-targeted viral vector delivery technologies to develop…
03 Oct 23
The acquisition equips Clade with preclinical cell therapy programmes, a g/d TCR discovery engine, and cell enhancement technologies…